Drugs / BM2216
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06846567 | Dec 2024 → Jan 2025 | diabetes mellitus, diabetic neuropathy | Zhejiang Anglikang Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BM2216 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06846567 ↗ |
| Route | Oral | “single oral administration” NCT06846567 ↗ |